CVA for CellDyn 291720

GUDID 00844509001591

Assayed linearity control kits that are used to determine the patient reportable range of 3-part and 5-part hematology instruments. Contains 1 vial each of PLT L1-6.

STRECK, INC.

Full blood count IVD, control
Primary Device ID00844509001591
NIH Device Record Keycb19a666-b882-4815-a1e8-fc0dda99c5f3
Commercial Distribution StatusIn Commercial Distribution
Brand NameCVA for CellDyn
Version Model Number291720
Catalog Number291720
Company DUNS072915986
Company NameSTRECK, INC.
Device Count1
DM Exempttrue
Pre-market Exemptfalse
MRI Safety StatusLabeling does not contain MRI Safety Information
Human Cell/Tissue Productfalse
Device Kittrue
Device Combination Productfalse
Single Usefalse
Lot Batchtrue
Serial Numberfalse
Manufacturing Datefalse
Expiration Datetrue
Donation Id Numberfalse
Contains Natural Rubber Latexfalse
Labeled No Natural Rubber Latexfalse
RX Perscriptionfalse
OTC Over-The-Counterfalse

Customer Support Contacts

Phone1-800-228-6090
Emailcustserv@streck.com

Device Dimensions

Total Volume3 Milliliter

Operating and Storage Conditions

Storage Environment TemperatureBetween 2 Degrees Celsius and 10 Degrees Celsius

Device Identifiers

Device Issuing AgencyDevice ID
GS100844509001591 [Primary]

FDA Pre-market Approvals/Notifications & deNovo

FDA Product Code

JPKMixture, Hematology Quality Control

Sterilization

Steralize Prior To Usefalse
Device Is Sterilefalse

Device Entry Metadata

Public Version StatusUpdate
Device Record StatusPublished
Public Version Number3
Public Version Date2018-07-06
Device Publish Date2016-09-16

On-Brand Devices [CVA for CellDyn ]

00844509001591Assayed linearity control kits that are used to determine the patient reportable range of 3-part
00844509001584Assayed linearity control kits that are used to determine the patient reportable range of 3-part
00844509001577Assayed linearity control kits that are used to determine the patient reportable range of 3-part
00844509001560Assayed linearity control kits that are used to determine the patient reportable range of 3-part

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.